CliffBio
small molecule

SAPHRIS

ASENAPINE MALEATE

Loss of exclusivityOctober 2026latest FDA-listed patent expiry
CompanyAbbVie Inc. →View the full company profile on CliffBio

Drug detail

Brand nameSAPHRIS
Active ingredientASENAPINE MALEATE
StrengthEQ 5MG BASE
Dosage formTABLET
RouteSUBLINGUAL
ModalitySmall molecule
FDA approvalAugust 2009
Marketing statusRX

Listed patents

PatentExpiresType
7741358*PEDOctober 2026—
8022228*PEDOctober 2026—
7741358April 2026substance, product
8022228April 2026substance, product

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

SAPHRIS patent cliff — loss of exclusivity October 2026 | CliffBio